Citation Impact
Citing Papers
An engineered 4-1BBL fusion protein with “activity on demand”
2020
Intracellular Tumor-Associated Antigens Represent Effective Targets for Passive Immunotherapy
2012 StandoutNobel
Immunotype and Immunohistologic Characteristics of Tumor-Infiltrating Immune Cells Are Associated with Clinical Outcome in Metastatic Melanoma
2012
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
2015 StandoutScience
Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients
2012
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
2008 Standout
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
2007 Standout
Treatment of kidney cancer
2009 StandoutNobel
Immunotherapy of cancer in 2012
2012
A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy
2022 StandoutNobel
Cancer statistics, 2017
2017 Standout
Cytokines and Vascular Permeability: An In Vitro Study on Human Endothelial Cells in Relation to Tumor Necrosis Factor-α-Primed Peripheral Blood Mononuclear Cells
2006
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Inflammation and cancer
2002 StandoutNature
Direct evidence for rapid and selective induction of tumor neovascular permeability by tumor necrosis factor and a novel derivative, colloidal gold bound tumor necrosis factor
2007
The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells
2012
Oncology Meets Immunology: The Cancer-Immunity Cycle
2013 Standout
Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment
2013
The von Hippel–Lindau tumour suppressor protein: O2 sensing and cancer
2008 StandoutNobel
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
mRNA-based therapeutics — developing a new class of drugs
2014 StandoutNobel
Growth factor-receptor pathway interfering treatment by somatostatin analogs and suramin: Preclinical and clinical studies
1990
Tumor necrosis factor, cancer and anticancer therapy
2004
Increased risk of incident HIV during pregnancy in Rakai, Uganda: a prospective study
2005
Clinical applications of TNF-α in cancer
1998
Immunotherapy for Metastatic Solid Cancers
2011
GENE THERAPY FOR MALIGNANT PLEURAL MESOTHELIOMA
1998
Management of malignant pleural mesothelioma: a critical review
2000
New approaches for mesothelioma: Biologics, vaccines, gene therapy, and other novel agents
2002
Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment
2010
Soft-Tissue Sarcomas in Adults
2005 Standout
Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity
2009 Standout
Sarcoidosis
2013 Standout
Macrophage Diversity Enhances Tumor Progression and Metastasis
2010 Standout
Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity
2017 StandoutNobel
Nuclear factor-κB in cancer development and progression
2006 StandoutNature
Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion
2001
Dendritic cells in cancer immunotherapy
2010
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
2011 StandoutNobel
Tumor-infiltrating lymphocytes: apparently good for melanoma patients. But why?
2011
Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
2010 Standout
Evidence for the involvement of endotheliai cell integrin αVβ3 in the disruption of the tumor vascuiature induced by TNF and IFN-γ
1998
Immunity, Inflammation, and Cancer
2010 Standout
The biology of the combretastatins as tumour vascular targeting agents
2002
Current uses of isolated limb perfusion in the clinic and a model system for new strategies
2003
The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans
2021 StandoutNobel
Inflammation and cancer: back to Virchow?
2001 Standout
Cancer immunotherapy
2012
Cancer immunotherapy comes of age
2011 StandoutNature
The blockade of immune checkpoints in cancer immunotherapy
2012 Standout
Idiopathic Pulmonary Fibrosis
2001 Standout
Management of malignant pleural effusions
2001 Standout
Microtubules as a target for anticancer drugs
2004 Standout
Repertoire Enhancement with Adoptively Transferred Female Lymphocytes Controls the Growth of Pre-Implanted Murine Prostate Cancer
2012 StandoutNobel
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
2015 StandoutNature
Tumour necrosis factor and cancer
2009
Tumor necrosis factor or tumor promoting factor?
2002
Sarcoidosis
2007 Standout
Cancer-related inflammation
2008 StandoutNature
Gold nanoparticles in biomedical applications: recent advances and perspectives
2011 Standout
Gene Signature in Melanoma Associated With Clinical Activity
2010
Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies
2006 Standout
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Type I interferons in anticancer immunity
2015
Pleural mesothelioma
1999
Maternal mortality: who, when, where, and why
2006 Standout
Advances in Malignant Mesothelioma
2005 Standout
Dengue
2007 Standout
Infliximab Therapy in Patients with Chronic Sarcoidosis and Pulmonary Involvement
2006
Sex Is an Independent Prognostic Indicator for Survival and Relapse/Progression-Free Survival in Metastasized Stage III to IV Melanoma: A Pooled Analysis of Five European Organisation for Research and Treatment of Cancer Randomized Controlled Trials
2013
SuFEx Click Chemistry Enabled Late-Stage Drug Functionalization
2018 StandoutNobel
Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma
2013
Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma
2012 StandoutNobel
Activation-Induced Cell Death Limits Effector Function of CD4 Tumor-Specific T Cells
2004
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
2011 StandoutScience
Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma
2010
Copper induces cell death by targeting lipoylated TCA cycle proteins
2022 StandoutScience
Unique potential of 4-1BB agonist antibody to promote durable regression of HPV + tumors when combined with an E6/E7 peptide vaccine
2015 StandoutNobel
Dendritic cells are specialized accessory cells along with TGF-β for the differentiation of Foxp3+ CD4+ regulatory T cells from peripheral Foxp3− precursors
2007 StandoutNobel
Cancer Genome Landscapes
2013 StandoutScience
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+regulatory T cells, evoking antitumor immune responses in humans
2013 StandoutNobel
Phase I and Pharmacokinetic Studies of CYT-6091, a Novel PEGylated Colloidal Gold-rhTNF Nanomedicine
2010
Emerging Targets in Photopharmacology
2016 StandoutNobel
Immune Therapy for Cancer
2008
Adjuvant Ganglioside GM2-KLH/QS-21 Vaccination Versus Observation After Resection of Primary Tumor > 1.5 mm in Patients With Stage II Melanoma: Results of the EORTC 18961 Randomized Phase III Trial
2013
The Pten/PI3K pathway governs the homeostasis of Vα14iNKT cells
2006 StandoutNobel
Works of A.M.M. Eggermont being referenced
Isolated limb perfusion with actinomycin D and TNF-alpha results in improved tumour response in soft-tissue sarcoma-bearing rats but is accompanied by severe local toxicity
2002
Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion
2000
TNF- α augments intratumoural concentrations of doxorubicin in TNF- α -based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects
2000
Prerequisites for effective isolated limb perfusion using tumour necrosis factor alpha and melphalan in rats
1999
Isolated Limb Perfusions With Tumor Necrosis Factor and Melphalan for Locally Recurrent Soft Tissue Sarcoma in Previously Irradiated Limbs
2005
Effects of isolated limb perfusion with tumour necrosis factor‐alpha on the function of monocytes and T lymphocytes in patients with cancer
1996
Regional treatment of metastasis: role of regional perfusion. State of the art isolated limb perfusion for limb salvage
2004
Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study
1995
Final results of the EORTC 18871/DKG 80-1 randomised phase III trial
2003
Utility of adjuvant systemic therapy in melanoma
2009
Isolated limb perfusion with tumor necrosis factor and melphalan for nonresectable Stewart-Treves lymphangiosarcoma
2002
Rationale for using TNFα and chemotherapy in regional therapy of melanoma
1994
Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- α versus toxicity after melphalan alone
2001
Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (MM): 1-year OS update.
2010
Protective effect of a brisk tumor infiltrating lymphocyte infiltrate in melanoma: An EORTC melanoma group study
2007
Systemic leakage during isolated limb perfusion for melanoma
1993
Interferon-α as adjuvant therapy for melanoma: An individual patient data meta-analysis of randomised trials
2007
Administration of high-dose tumor necrosis factor alpha by isolation perfusion of the limbs. Rationale and results.
1995
Expression of defined genes identified by pretreatment tumor profiling: Association with clinical responses to the GSK MAGE- A3 immunotherapeutic in metastatic melanoma patients (EORTC 16032–18031)
2008
Solid Tumor Therapy: Manipulation of the Vasculature with TNF
2003
EORTC 18991: Long-term adjuvant pegylated interferon-alpha2b (PEG-IFN) compared to observation in resected stage III melanoma, final results of a randomized phase III trial
2007
EORTC 18991 phase III trial: Long-term adjuvant pegylated interferon-α2b (PEG-IFN) versus observation in resected stage III melanoma: Long-term results at 7.6-years follow-up.
2011
Suramin: Pharmacokinetic monitoring, haematological and antitumor effects on rats bearing transplantable pancreatic tumors
1990
Isolation limb perfusion with tumor necrosis factor alpha and chemotherapy for advanced extremity soft tissue sarcomas.
1997
Synergistic antitumour effect of recombinant human tumour necrosis factor a with melphalan in isolated limb perfusion in the rat
1996
EORTC 18961: Post-operative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II (T3-T4N0M0) melanoma: 2nd interim analysis led to an early disclosure of the results
2008